Blood Test Can Predict Fatty Liver Disease
Medically reviewed by Drugs.com.
By Dennis Thompson HealthDay Reporter
FRIDAY, April 25, 2025 -- Doctors can accurately predict a person’s risk of fatty liver disease as early as 16 years before symptoms develop, a new study says.
A blood test looking for five specific proteins can predict metabolic dysfunction-associated steatotic liver disease (MASLD), more commonly known as fatty liver disease, researchers are scheduled to report at the upcoming Digestive Diseases Week meeting in San Diego.
The five-protein test was 84% accurate at predicting fatty liver disease five years from onset and 76% accurate at predicting 16 years ahead of diagnosis, researchers report.
“Too often, people do not find out they are at risk for liver disease before they are diagnosed and coping with symptoms,” lead researcher Dr. Shiyi Yu said in a news release. Yu is a resident physician of gastroenterology at Guangdong Provincial People's Hospital in China.
“The field urgently needs effective biomarkers and predictive models, and our research shows that plasma proteins offer novel potential strategies for early prediction and intervention,” Yu added.
Fatty liver disease occurs when fat starts to accumulate in the liver, eventually causing inflammation and scarring. People with the disorder face up to twice the risk of premature death as those without fatty liver disease, researchers said in background notes.
For the study, researchers analyzed blood samples from more than 50,000 people participating in the UK Biobank, a long-term U.K. health research study.
The team screened for more than 2,700 blood-borne proteins and found five that appear to be early warning signals for fatty liver disease.
Adding other clues of fatty liver disease, like body mass index (an estimate of body fat based on height and weight) and daily exercise, boosted the blood test’s accuracy even more – more than 90% at five years and 82% at 16 years.
“We achieved similar results when we tested this predictive model in a separate cohort of people in China, further supporting the robustness of the model and showing it can be effective across diverse populations,” Yu said.
Yu is scheduled to present these findings on May 4. Findings presented at medical meetings are considered preliminary until published in a peer-reviewed journal.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-04-26 00:00
Read more

- Infant with Carbamoyl Phosphate Synthetase 1 (CPS1) Deficiency First to Successfully Receive Personalized Gene Therapy Treatment
- Pheast Therapeutics Receives FDA Fast Track Designation for PHST001 for the Treatment of Ovarian Cancer
- Colorado Reporting New Outbreak of Measles
- Mailed Self-Collection Kits Increase Rates of Cervical Cancer Screening
- Most People With Cannabis Use Disorder Remain Untreated
- Kids Snooze Soundly In Happy Families
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions